文献速递前列腺癌

比较蛋白质组与血清分析鉴定FSCN1为去势抵抗性前列腺癌阿比特龙耐药标志物

Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2023-08-26

本研究对阿比特龙敏感与 resistant 前列腺癌细胞系行 LC-MS/MS 比较蛋白质组分析,筛选候选血清标志物,并在 100 例阿比特龙治疗的转移性去势抵抗性前列腺癌患者及 69 例多西他赛治疗患者中用 ELISA 检测血清水平。结果显示基线 FSCN1 血清水平高与阿比特龙治疗患者生存差显著相关,且为独立预后因素,而与多西他赛治疗患者总生存无关。

要点

  • 基线 FSCN1 血清水平高与阿比特龙治疗的 mCRPC 患者生存差显著相关。
  • 多变量分析显示 ECOG>1 与基线 FSCN1>10.22 ng/ml 独立与更差生存相关(p<0.001 和 p=0.021)。
  • 多西他赛治疗患者中血清 FSCN1 浓度与总生存无关联。

核心结论

  • 基线 FSCN1 血清水平独立与阿比特龙治疗而非多西他赛治疗的 mCRPC 患者生存差相关,提示 FSCN1 具有治疗特异性预后价值。

研究设计与样本

  • 研究对三种阿比特龙敏感(LNCaPabl、LAPC4、DuCaP)和三种耐药(LNCaPabl-Abi、LAPC4-Abi、DuCaP-Abi)前列腺癌细胞系行 LC-MS/MS 比较蛋白质组分析。
  • 用两种生物信息学筛选流程选择候选血清标志物,并用 ELISA 在 100 例阿比特龙治疗的转移性去势抵抗性前列腺癌患者样本中检测所选蛋白血清水平。
  • 另在 69 例多西他赛治疗的 mCRPC 患者样本中检测 FSCN1 血清浓度。

主要发现

  • 蛋白质组分析在阿比特龙耐药细胞中鉴定出 68 个显著至少上调两倍的蛋白。
  • 通过两种过滤流程选出四种蛋白(AMACR、KLK2、FSCN1 和 CTAG1A)用于 ELISA 分析。
  • 发现基线 FSCN1 血清水平高与阿比特龙治疗的 mCRPC 患者生存差显著相关。
  • 多变量分析显示较高 ECOG 状态(>1)和高基线 FSCN1 血清水平(ROC 截断值 >10.22 ng/ml)独立与阿比特龙治疗患者更差生存相关(p < 0.001 和 p = 0.021)。
  • 多西他赛治疗患者中血清 FSCN1 浓度与总生存无关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Abiraterone (Abi) is an androgen receptor signaling inhibitor that significantly improves patients' life expectancy in metastatic prostate cancer (PCa). Despite its beneficial effects, many patients have baseline or acquired resistance against Abi. The aim of this study was to identify predictive serum biomarkers for Abi treatment. METHODS: We performed a comparative proteome analysis on three Abi sensitive (LNCaPabl, LAPC4, DuCaP) and resistant (LNCaPabl-Abi, LAPC4-Abi, DuCaP-Abi) PCa cell lines using liquid chromatography tandem mass spectrometry (LC-MS/MS) technique. Two bioinformatic selection workflows were applied to select the most promising candidate serum markers. Serum levels of selected proteins were assessed in samples of 100 Abi-treated patients with metastatic castration-resistant disease (mCRPC) using ELISA. Moreover, FSCN1 serum concentrations were measured in samples of 69 Docetaxel (Doc) treated mCRPC patients. RESULTS: Our proteome analysis identified 68 significantly, at least two-fold upregulated proteins in Abi resistant cells. Using two filtering workflows four proteins (AMACR, KLK2, FSCN1 and CTAG1A) were selected for ELISA analyses. We found high baseline FSCN1 serum levels to be significantly associated with poor survival in Abi-treated mCRPC patients. Moreover, the multivariable analysis revealed that higher ECOG status (>1) and high baseline FSCN1 serum levels (>10.22 ng/ml by ROC cut-off) were independently associated with worse survival in Abi-treated patients (p < 0.001 and p = 0.021, respectively). In contrast, no association was found between serum FSCN1 concentrations and overall survival in Doc-treated patients. CONCLUSIONS: Our analysis identified baseline FSCN1 serum levels to be independently associated with poor survival of Abi-treated, but not Doc-treated mCRPC patients, suggesting a therapy specific prognostic value for FSCN1.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Csizmarik A, Nagy N, Keresztes D, et al. Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2023. PMID: 37634036. doi:10.1038/s41391-023-00713-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。